scholarly journals Genotype Distribution of Human Papillomavirus among Women with Cervical Cytological Abnormalities or Invasive Squamous Cell Carcinoma in a High-Incidence Area of Esophageal Carcinoma in China

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Yuanyuan Wang ◽  
Shaohong Wang ◽  
Jinhui Shen ◽  
Yanyan Peng ◽  
Lechuan Chen ◽  
...  
Keyword(s):  
High Risk ◽  
Cervical Cytology ◽  
Invasive Squamous Cell Carcinoma ◽  
Genotype Distribution ◽  
Normal Cytology ◽  
Hpv 16 ◽  
High Incidence ◽  
Hpv Types ◽  
High Risk Hpv ◽  
High Incidence Area

Data of HPV genotype including 16 high-risk HPV (HR-HPV) and 4 low-risk HPV from 38,397 women with normal cytology, 1341 women with cervical cytology abnormalities, and 223 women with ISCC were retrospectively evaluated by a hospital-based study. The prevalence of high-risk HPV (HR-HPV) was 6.51%, 41.83%, and 96.86% in women with normal cytology, cervical cytology abnormalities, and ISCC, respectively. The three most common HPV types were HPV-52 (1.76%), HPV-16 (1.28%), and HPV-58 (0.97%) in women with normal cytology, whereas the most prevalent HPV type was HPV-16 (16.85%), followed by HPV-52 (9.55%) and HPV-58 (7.83%) in women with cervical cytology abnormalities. Specifically, HPV-16 had the highest frequency in ASC-H (24.16%, 36/149) and HSIL (35.71%, 110/308), while HPV-52 was the most common type in ASC-US (8.28%, 53/640) and LSIL (16.80%, 41/244). HPV-16 (75.78%), HPV18 (10.31%), and HPV58 (9.87%) were the most common types in women with ISCC. These data might contribute to increasing the knowledge of HPV epidemiology and providing the guide for vaccine selection for women in Shantou.

scholarly journals Human Papillomavirus Type Distribution and Correlation with Cyto-Histological Patterns in Women from the South of Italy

2009 ◽  
Vol 2009 ◽  
pp. 1-4 ◽  
Author(s):  
Paola Menegazzi ◽  
Luisa Barzon ◽  
Giorgio Palù ◽  
Elisa Reho ◽  
Luigi Tagliaferro
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Hpv Infection ◽  
Multiple Infection ◽  
Multiple Infections ◽  
The South ◽  
Hpv 16 ◽  
Specific Distribution ◽  
Hpv Types ◽  
High Risk Hpv

Human papillomavirus (HPV) type-specific distribution was evaluated in genital samples collected from 654 women from the South of Italy undergoing voluntary screening and correlated with cyto-histological abnormalities. HPV DNA was detected in 45.9% of the samples, 41.7% of which had multiple infection and 89.0% had high-risk HPV infection. The prevalence of HPV infection and the rate of multiple infections decreased with age, suggesting natural selection of HPV types with better fitness. In line with other Italian studies, the most common HPV types were HPV-6 and HPV-16, followed by HPV-51, HPV-31, HPV-53, and HPV-66, in women with both normal and abnormal cytology. Cervical intraepithelial lesions grade 2 or 3 were associated with high-risk HPV-16, HPV-18, HPV-31, and HPV-51 infection. These data indicate that prophylactic HPV vaccination is expected to reduce the burden of HPV-related cervical lesions in this population, but also suggest the potential utility of new vaccines with larger type coverage.

scholarly journals Expression of the high-risk human papillomavirus type 18 and 45 E7 oncoproteins in cervical carcinoma biopsies

2005 ◽  
Vol 86 (12) ◽  
pp. 3235-3241 ◽  
Author(s):  
Marc Fiedler ◽  
Sigrun Ressler ◽  
Beatriz Campo-Fernández ◽  
Andreas Laich ◽  
Lars Jansen ◽  
...  
Keyword(s):  
High Risk ◽  
Cervical Carcinoma ◽  
Human Papillomaviruses ◽  
Hpv 16 ◽  
Cervical Cancers ◽  
Hpv Types ◽  
High Level ◽  
E7 Proteins ◽  
High Risk Hpv ◽  
Hpv 18

E7 proteins are major oncoproteins of high-risk human papillomaviruses (HPVs), which play a key role in cervical carcinogenesis. These proteins have been shown to immortalize primary human cells. Due to the absence of antibodies with suitable sensitivity and specificity, little is known about expression of the E7 oncoproteins in naturally infected tissues. Recently, high-level expression of the E7 protein of HPV-16, the most prevalent oncogenic HPV type, was demonstrated in cervical carcinomas by immunohistochemistry; however, approximately 15 additional high-risk HPV types are known to be associated with cervical carcinoma. It is unknown whether the E7 oncoproteins of HPV-18 and -45, the second and third most prevalent HPV types, are expressed in cervical cancers. Using antibodies against HPV-18 and -45 E7 proteins, it is shown here for the first time that the HPV-18 and -45 E7 proteins can be detected in cervical carcinoma biopsies. Together with anti-HPV-16 E7 antibodies, this could create the possibility of detecting E7 oncoproteins in approximately 80 % of all cervical cancers.

scholarly journals Clinico-epidemiological profile of condylomata acuminata with special emphasis on HPV typing

2017 ◽  
Vol 3 (3) ◽  
pp. 332
Author(s):  
A. Sarin ◽  
V. G. Binesh ◽  
Betsy Ambooken ◽  
S. Suprakasan
Keyword(s):  
High Risk ◽  
Condylomata Acuminata ◽  
Transmitted Infection ◽  
Hpv 16 ◽  
Sexually Transmitted ◽  
Hbsag Positivity ◽  
Hpv Typing ◽  
Hpv Types ◽  
Epidemiological Profile ◽  
High Risk Hpv

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">Condylomata acuminata (CA) or genital wart is a sexually transmitted infection (STI) caused by human papilloma virus (HPV). As there was little information about the HPV types commonly causing CA in our state, we decided to study the clinico-epidemiological profile of CA with special emphasis on HPV typing.</span></p><p class="abstract"><strong>Methods:</strong> We did <span lang="EN-IN">HPV typing in 25 clinically diagnosed cases of CA. The biopsied specimens were sent for HPV typing using Polymerase chain reaction (PCR) and those with high risk HPV types were histologically analyzed for any dysplastic change. We also evaluated for other STIs which can coexist with CA</span>.<strong></strong></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">Out of the 25 cases, 18 (72%) were males and 7 (28%) females. Majority of our patients belonged to 21-40 year age group (64%). Clinical types of CA were the classical fleshy exuberant type in 22 patients (88%), flat type in 2 (8%) and keratotic type in 1 (4%). HPV positivity was obtained in 21 (84%). The most common type was HPV 6 in 10 cases (40%) and HPV 11 in 8 (32%) patients. HPV 16 alone was isolated in 1 (4%) case. HPV types 6 and 16 and 11 &amp; 18 were isolated in one case each. Dysplastic changes were observed in two cases with HPV 16 and 18. VDRL and TPHA positivity was found in 2 (8%) males and HBsAg positivity was seen in 1 (4%) male patient. </span></p><p class="abstract"><strong>Conclusions:</strong> <span lang="EN-IN">This study highlights the importance of HPV typing for identifying the high risk types and to assess the efficacy of HPV vaccines.</span></p>

Human papillomavirus prevalence to age 60 years among Australian women prevaccination

Sexual Health ◽  
2015 ◽  
Vol 12 (4) ◽  
pp. 353 ◽  
Author(s):  
Julia M. L. Brotherton ◽  
John R. Condon ◽  
Peter B. McIntyre ◽  
Sepehr N. Tabrizi ◽  
Michael Malloy ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Sexual Debut ◽  
Cervical Screening ◽  
Hpv Vaccination ◽  
Normal Cytology ◽  
Screening Programs ◽  
Hpv Types ◽  
High Risk Hpv ◽  
Second Peak

Background The prevalence of human papillomavirus (HPV) at the cervix varies with age, peaking following sexual debut and declining thereafter in most populations. In some populations, a second peak is observed. Here we describe the prevalence of HPV at the cervix among Australian women before the commencement of the HPV vaccination program. Methods: Women aged 15 to 60 years attending health services for cervical screening between 2005 and 2008 were invited to participate. Liquid based cervical specimens were tested for 37 types of HPV using linear array. The percentage and 95% confidence interval of women with any type of HPV, any of 13 high risk HPV types, and with vaccine-preventable HPV types (types 6, 11, 16 and 18) were estimated in 5-year age bands. Results: Among 1929 women aged 15–60 years, HPV prevalence peaked at 64% at age 15–20 years, then declined gradually to 12% at age 41–45 years, whereafter it rose to 19% in women 51–55 years then returned to 14% in 56–60 year olds. Prevalence curves were similar for high-risk HPV types and vaccine-targeted HPV types 6, 11, 16 and 18 and when results were restricted to women with only normal cytology. Conclusions: The shape of the prevalence curve we observed is similar to those from other Western populations. Variation in prevalence curves is likely due to differences in sexual behaviour between populations and over time, reactivation of HPV during perimenopause, and possibly the presence of cervical screening programs. These data are the first such data from the Oceania region.

scholarly journals The presence and distribution of high risk HPV types in simultaneous cervical cytology samples

2018 ◽  
Vol 75 (1) ◽  
pp. 13-20
Author(s):  
Sibel Aydoğan ◽  
Aylin Yazgan ◽  
Emre Erdem Taş ◽  
Ayşegül Gözalan ◽  
Ayşe Filiz Yavuz ◽  
...  
Keyword(s):  
High Risk ◽  
Cervical Cytology ◽  
Hpv Types ◽  
High Risk Hpv

High-risk human papillomavirus (HPV) detection in formalin-fixed paraffin-embedded cervical tissues: performances of Aptima HPV assay and Beckton Dickinson (BD) Onclarity assay

2021 ◽  
pp. jclinpath-2021-207657
Author(s):  
Gozde Kir ◽  
Humeyra Gunel ◽  
Zeynep Cagla Olgun ◽  
W Glenn McCluggage
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Hpv 16 ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Ffpe Tissues ◽  
Hpv Types ◽  
High Risk Hpv ◽  
Hpv Assays ◽  
Formalin Fixed

AimThere are many scenarios where high-risk human papillomavirus (HPV) detection in formalin-fixed paraffin-embedded (FFPE) specimens is important. However, there is no Food and Drug Administration (FDA)-approved and clinically validated technique for detecting high-risk HPV in FFPE tissues. In this study, we evaluated two commercially available HPV assays which are FDA-approved for use on cytology specimens, the Aptima HPV assay and the Beckton Dickinson (BD) Onclarity assay, to detect high-risk HPV in FFPE tissues of cervical high-grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma (SCC).MethodsA total of 189 cases (46 SCC, 107 HSIL and 36 benign/normal) were tested for high-risk HPV with the Aptima HPV assay and a subset of cases (n=97) with the BD Onclarity assay.ResultsThe sensitivities of the Aptima and BD Onclarity HPV assays were 99.4% (95% CI 96.46% to 99.98%) and 75.9% (95% CI 65.27% to 84.62%), respectively; the specificity and positive predictive value (PPV) of the two assays were 100%. Negative predictive values of the Aptima and BD Onclarity HPV assays were 97.3% (95% CI 83.61% to 99.61%) and 67.7% (95% CI 58.91% to 75.47%), respectively. The kappa value (0.96) for comparison of the distribution of high-risk HPV types between the two assays was high. HPV 16 was the most common high-risk HPV type for HSIL and SCC cases. However, SCC cases had higher percentages of HPV 16 and HPV 18/45 and lower percentages of other high-risk HPV types compared with HSIL cases.ConclusionBoth assays are reliable methods for high-risk HPV detection and genotype determination in FFPE specimens, with high PPV and specificity. The Aptima HPV assay has the advantage of higher sensitivity. As far as we are aware, this is the first study comparing the Aptima HPV assay and the BD Onclarity assay in FFPE tissues. Our study results should be tested and confirmed in larger cohorts.

scholarly journals Prevalence of High-Risk HPV Types and Abnormal Cervical Cytology in American Indian/Alaska Native Women, 2003–2005

2011 ◽  
Vol 126 (3) ◽  
pp. 330-337 ◽  
Author(s):  
Grace A. Alfonsi ◽  
S. Deblina Datta ◽  
Theresa Mickiewicz ◽  
Laura A. Koutsky ◽  
Khalil Ghanem ◽  
...  
Keyword(s):  
High Risk ◽  
American Indian ◽  
Alaska Native ◽  
Cervical Cytology ◽  
Native Women ◽  
Abnormal Cervical Cytology ◽  
Hpv Types ◽  
High Risk Hpv

scholarly journals Cross-Reactivity, Epitope Spreading, andDe NovoImmune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines

2015 ◽  
Vol 22 (7) ◽  
pp. 679-687 ◽  
Author(s):  
Mayumi Nakagawa ◽  
William Greenfield ◽  
Andrea Moerman-Herzog ◽  
Hannah N. Coleman
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Hpv Infection ◽  
Cross Reactivity ◽  
Cross Protection ◽  
Epitope Spreading ◽  
Therapeutic Vaccines ◽  
Hpv 16 ◽  
Hpv Types ◽  
High Risk Hpv

ABSTRACTNumerous versions of human papillomavirus (HPV) therapeutic vaccines designed to treat individuals with established HPV infection, including those with cervical intraepithelial neoplasia (CIN), are in development because approved prophylactic vaccines are not effective once HPV infection is established. As human papillomavirus 16 (HPV-16) is the most commonly detected type worldwide, all versions of HPV therapeutic vaccines contain HPV-16, and some also contain HPV-18. While these two HPV types are responsible for approximately 70% of cervical cancer cases, there are other high-risk HPV types known to cause malignancy. Therefore, it would be of interest to assess whether these HPV therapeutic vaccines may confer cross-protection against other high-risk HPV types. Data available from a few clinical trials that enrolled subjects with CINs regardless of the HPV type(s) present demonstrated clinical responses, as measured by CIN regression, in subjects with both vaccine-matched and nonvaccine HPV types. The currently available evidence demonstrating cross-reactivity, epitope spreading, andde novoimmune stimulation as possible mechanisms of cross-protection conferred by investigational HPV therapeutic vaccines is discussed.

Sign in / Sign up

Export Citation Format

Share Document